Earnings Feed
Start Free
Spero Therapeutics, Inc.·4

Feb 5, 6:30 AM ET

Keutzer Timothy 4

Research Summary

AI-generated summary

Updated

Spero Therapeutics COO Timothy Keutzer Sells Shares, Receives RSUs & Options

What Happened

  • Timothy Keutzer, Chief Operating Officer of Spero Therapeutics (SPRO), reported sales totaling 46,586 shares across Feb 2–4, 2026 for proceeds of about $101,174, and received equity awards on Feb 2, 2026: 68,000 restricted stock units (RSUs) and a derivative award covering 137,000 shares (stock option grant).
  • Sales detail: 18,891 shares sold on 2026-02-02 at $2.20 ($41,560), 24,224 shares sold on 2026-02-03 at $2.14 ($51,839), and 3,471 shares sold on 2026-02-04 at $2.24 ($7,775). The RSUs and option grant were reported at $0.00 acquisition price (standard for awards).

Key Details

  • Transaction dates & prices:
    • 2026-02-02: 18,891 shares sold @ $2.20 (F2)
    • 2026-02-03: 24,224 shares sold @ $2.14
    • 2026-02-04: 3,471 shares sold @ $2.24
    • 2026-02-02: 68,000 RSUs granted (A)
    • 2026-02-02: 137,000-share derivative award (A, option)
  • Shares owned after transaction: Not specified in the provided filing excerpt.
  • Footnotes of note:
    • F1: 68,000 RSUs — each converts to one share; vest in four equal annual installments beginning Feb 2, 2027, subject to continued service.
    • F2: The 18,891-share sale was a sell-to-cover to satisfy tax withholding on vesting RSUs (automatic, not a discretionary trade).
    • F3: The 137,000-share derivative (option) vests 25% on Feb 2, 2027, then monthly over the next 36 months, subject to continued service.
  • Filing date: Form filed Feb 5, 2026. (No late-filing flag was provided in the excerpt.)

Context

  • The reported sale on Feb 2 was an automatic sell-to-cover for tax withholding related to RSU vesting (not an active market-timing decision). The other sales were open-market disposals.
  • The awards are standard compensation grants (RSUs and options) with multi-year vesting schedules; option grant details indicate future vesting, not immediate exercised-and-sold shares.
  • For retail investors, award grants are routine executive compensation; sell-to-cover transactions are common and do not necessarily indicate negative insider sentiment.